Updates

Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com BIO/SECL/TG/2026-27/61 August 25, 2026 To To The Manager, The Manager, BSE Limited National Stock Exchange of India Limited Department of Corporate Services Corporate Communication Department Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai – 400 001 Mumbai – 400 051 Scrip Code - 532523 Scrip Symbol - BIOCON Subject: Company Statement Dear Sir/Madam, Please find enclosed Company Statement w.r.t. “Biocon Announces Pegfilgrastim Biosimilar Marketing Approval by Japan Ministry of Health, Labour and Welfare (MHLW)”. The above information will also be available on the website of the Company at www.biocon.com. Kindly take the same on record and acknowledge. Thanking You, Yours faithfully, For Biocon Limited Rajesh U. Shanoy Company Secretary and Compliance Officer M. No.: ACS 16328 Encl: Company Statement NOTIFICATION TO STOCK EXCHANGE COMPANY STATEMENT Biocon Announces Pegfilgrastim Biosimilar Marketing Approval by Japan Ministry of Health, Labour and Welfare (MHLW) Bengaluru, Karnataka, India, August 25, 2026 Biocon Biologics Ltd., a wholly-owned subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), received marketing approval for its pegfilgrastim biosimilar (“Product”) from Japan’s Ministry of Health, Labour and Welfare (MHLW). The product, a biosimilar to Neulasta®, is developed and manufactured by Biocon Biologics Ltd, parent entity of Biocon Biologics UK PLC (Biocon Biologics Ltd and Biocon Biologics UK PLC shall be collectively referred to as “Biocon”), with Global Regulatory Partners Japan serving as the Marketing Authorization Holder on behalf of Biocon. Sandoz K.K. shall exclusively promote, sell, and distribute the Product in Japan. This approval further strengthens Biocon’s portfolio of biosimilar products in Japan and reaffirms the company’s commitment to increasing patient access to high-quality and affordable medications globally. – Company Spokesperson Neulasta® is a registered trademark of Amgen Inc.